Prediction of Recurrence and Therapy Response in the Node Negative Breast Cancer Patient by DNA Flow Cytometry

Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.

DC Allred;R Molina;AK Tandon;SJ Schnitt;KW Gilchrist;CK Osborne;DC Tormey;WL McGuire Human Pathology 23(9):974-979

Prognostic potential of DNA flow cytometry measurements in node-negative breast cancer patients: Preliminary analysis of an Intergroup study (INT-0076).

LG Dressler;L Eudey ;R Gray;DC Tormey;WL McGuire;KW Gilchrist;CK Osborne;EG Mansour;MD Abeloff JNCI Monographs 11:167-172

HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by presence in in situ carcinoma.

DC Allred;AK Tandon;R Molina;DC Tormey;CK Osborne;KW Gilchrist;EG Monsour;M Abeloff;L Eudey;WL McGuire JCO 10:599-605

DNA flow cytometry measurements are prognostic for the time to recurrence in node negative breast cancer: An Eastern Cooperative Group (ECOG) intergroup study.

LG Dressler;L Eudey;R Gray;DC Tormey;WL McGuire;CK Osborne;KW Gilchrist;EG Mansour;MD Abeloff ASCO 9:22(#81)

Immunocytochemical analysis of HER-2/neu oncogene expression in in situ and invasive breast carcinoma: evaluation of pathological characteristics and biological significance.

DC Allred;R Molina;AK Tandon;CK Osborne;DC Tormey;KW Gilchrist;WL McGuire Modern Pathology 3(1):34